Tirz (G.L.P) (TR) is an investigational synthetic dual-agonist peptide that activates the G.I.P and G.L.P-1 receptors.
$104.00
11 in stock
11 in stock
Tirz (G.L.P) (TR) is an investigational synthetic dual-agonist peptide that activates the G.I.P and G.L.P-1 receptors. It is a linear 39-amino-acid peptide that has been designed to contain a C20 fatty diacid chain via γ-glutamic acid spacer for prolonged circulating half-life and once-weekly pharmacokinetics.
Tirz (G.L.P) has been investigated through in vitro lab research and observed challenges, including insulin secretion, blood glucose homeostasis, appetite regulation, body weight loss, triglyceride metabolism, and gastrointestinal motility. US-manufactured and supplies as high-purity lyophilized powder (≥99% via HPLC) in 20mg vials. Tirz (G.L.P) is for laboratory research use only in vitro and in vivo — it is not to be administered to humans, or used therapeutically or for any non-research purpose.
For research use only. Strictly not for human consumption.Tirz (G.L.P) Mechanism of Action in Research
Tirz (G.L.P) has a high affinity for and activates both G.I.P and G.L.P-1 receptors (family II G-protein-coupled receptors), stimulating G_s-protein signaling pathways and increasing intracellular cyclic AMP (cAMP) levels in target cells. Such dual agonism confers synergistic actions:
When activated, the G.L.P-1 receptor has anti-obesity effects through signalling in the central nervous system to suppress appetite, delay gastric emptying, and promote glucose-dependent insulin secretion while also repressing glucagon release when hyperglycaemic.
G.I.PR activation stimulates insulin secretion, enhances beta-cell functional reserve and regulates adipocyte lipid metabolism.
They describe a C20 fatty acid modification that allows for albumin binding, resulting in an extended plasma half-life of approximately 5 days and support for continued receptor activation in experimental models. These pathways are explored extensively in studies of metabolism regulation, energy balance, insulin sensitivity, and obesity-associated pathophysiology.
Tirz (G.L.P) Peptide Sequence
Tirz (G.L.P) is a 39-amino acid linear peptide, C-terminal amidated and lipidated:
Tyr-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂(C20 diacid connected via γ-Glu linker at Lys²⁰)
C₂₂₅H₃₄₈N₄₈O₆₈ (approximate; lipidated)
≈4813 Da
2023788-19-2
The lipid chain and requisite amino acid substitutions increase pharmacokinetic stabilities and receptor specificities.
Tirz (G.L.P) (0.1–10 nmol/kg s.c.) enhances glycemic control in preclinical models by increasing glucose-dependent insulin secretion and decreasing glucagon during hyperglycemia. In rodent studies, reductions in HbA1c-equivalent markers and fasting glucose can be stronger than those of G.L.P-1-only agonists, depending on the measures used.
Dosage-dependent weight loss (up to 20–30% body weight change compared to placebo at higher doses, sustained over 12 weeks) in obese animal studies has been shown with tirzepatide. It inhibits feeding through G.L.P-1 and G.I.P receptor stimulation within the central nervous system, resulting in reduced meal size and frequency. Preferred fat mass loss with preservation of lean tissue is associated with greater energy expenditure and higher rates of lipid oxidation, according to the evidence.
In the high-fat diet model, Tirz (G.L.P) significantly decreases levels of circulating triglycerides, LDL cholesterol, and free fatty acids but improves the HDL profile. It attenuates liver steatosis and enhances insulin sensitivity in both liver and adipose tissue. There are positive effects in cardiovascular studies on blood pressure, endothelial function and atherosclerosis markers in preclinical atherosclerosis models.
Tirz (G.L.P) has been shown to have neuroprotective effects in neuronal cultures and animal models of neurodegeneration. It exerts anti-inflammatory effects by suppressing microglial activation and proinflammatory cytokine release. Research investigates its role in Alzheimer’s, Parkinson’s, and stroke models through G.L.P-1/G.I.P-driven anti-apoptotic and neurotrophic signaling.
Tirz (G.L.P) is investigational — there is yet to be any large-scale, human approvable indication outside obesity/diabetes. Current investigations into the dual-agonist modes of action in metabolic homeostasis, energy balance, neuroprotection, and inflammation resolution are ongoing.Unopened vials are stored at room temperature at 2–8°C and protected from light and moisture. Do not freeze. Resuspend by aseptic addition of bacteriostatic water or sterile diluent. Refrigerate reconstituted solutions. Use within the stability window of the protocol (usually 4–6 weeks at 2–8°C). Avoid repeated freeze-thaw cycles. Every time, use sterile technique, gloves, and proper PPE.
Tirz (G.L.P) is an experimental research peptide. For in vitro or in vivo laboratory studies only. Not approved for therapeutic, metabolic, weight management, or any other human medical use by the FDA, EMA or any authority except as part of certain clinical trials. Information is based on data up until October 2023. Preclinical data do not correlate with human outcomes. No claims are made about safety, efficacy, or benefits in humans. Potential risks include immunogenicity or impurities. Only in qualified research facilities with institutional oversight. For laboratory use only — not for human or veterinary consumption.
This compound is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in diagnostic or therapeutic procedures.
| Molecular Formula | C225H348N48O68 |
| Molecular Mass | 4813 g/mol |
| Monoisotopic Mass | 4810.5248574 Da |
| Polar Area | ~1790 Ų |
| Complexity | 11700 |
| XLogP | -6.8 |
| Heavy Atom Count | 341 |
| Hydrogen Bond Donor Count | 58 |
| Hydrogen Bond Acceptor Count | 70 |
| Rotatable Bond Count | 163 |
| CID | 156588324 |
| InChI | InChI=1S/C225H348N48O68/c1-23-126(10)183(214(327)242-131(15)190(303)… |
| InChIKey | AAPYRSPHYSKGIS-MCNPHUAVSA-N |
| IUPAC Name | (2S)-2-[[20-[[(5S)-6-[[(2S,3S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2-methylpropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-6-oxohexyl]amino]-20-oxoicosanoyl]amino]-5-[2-[2-[2-[2-[2-(carboxymethoxy)ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-5-oxopentanoic acid |
| SMILES | CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C(C)(C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=CC=C9)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N |
Every batch of Tirz (G.L.P) (G.L.P-1/G.I.P) – 20mg is tested for purity and identity using industry-standard methods.
High-Performance Liquid Chromatography confirms purity ≥99%. Each batch is analyzed to ensure consistent quality.
Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol.
All compounds undergo independent third-party laboratory testing for quality assurance.
Certificate of Analysis documents are available for all compounds. Contact us with your order number to request batch-specific documentation.
Each compound batch is tested by independent laboratories to verify purity, identity, and quality. The Certificate of Analysis (COA) provides transparent lab results, ensuring the compound meets strict research-grade standards.
| Test | Method | Result | Specification | |
|---|---|---|---|---|
| Identity | HPLC-DAD | Tirzepatide | Tirzepatide | Pass |
| Purity | HPLC-DAD | 99.16 | >99% by HPLC | Pass |
| Quantity | HPLC Analyte Concentration Curve Assay | 20.11 | 20mg | Pass |
| Endotoxins | LAL ELISA | 0.128 EU/mL | ≤ 0.5 EU/mL | Pass |
| Sterility | Pour Plate | No Growth | No Growth | Pass |
This site supplies research compounds strictly for laboratory research. You must confirm both statements below to enter.
Compounds are supplied for laboratory research use only and are not for human or veterinary use.
